When a Space Shot Turns into a Science Mission, Your Portfolio Should Phone Home

Sometimes Wall Street hands you a moonshot with receipts.

A pair of Mars-bound craft just rolled into Florida, timelines look tight, and the thesis is less sci-fi and more cash-flow-ify. Let’s talk trajectories, not just telescopes.

Strong Setups Now (Sponsored)

5 Market Setups Too Strong to Overlook

“Nice gains” are fine. But if you’re serious about wealth-building, you don’t want fine—you want transformational.

That’s why our analysts went beyond the noise, screening thousands of companies to uncover 5 rare setups with the potential to deliver massive growth.

And here’s the kicker: past editions of this report have uncovered stocks that went on to post extraordinary runs of +175%, +498%, even +673%.¹

While no one can guarantee the future, history shows these reports have consistently spotted big opportunities before they took off.

For a limited time, you can download 5 Stocks Set to Double—absolutely free.

But there’s urgency: this free access expires at midnight tonight.

[Claim your free copy before time runs out] 

Don’t settle for “nice.” Go after what could be extraordinary.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Caterpillar | CAT

Price: $471.70

Rates eased, financing big iron got cheaper, and demand plus backlog is doing the heavy lifting.

Even with tariff noise earlier in the year, momentum and order books have pushed the shares into fresh-high territory.

Cyclicals like this can run longer than feels comfortable when capex cycles and public-spend tailwinds rhyme.

With this stock, don’t chase rips, and buy dips. Scale in on 5–8% pullbacks or when weekly RSI cools off.

Keep an eye on the three gauges of dealer inventory, price realization vs. input costs, and order intake in construction and mining.

If dealer inventories stay disciplined and price-cost spread holds, the upcycle still has fuel. Consider pairing CAT with a more defensive industrial to smooth the ride.

Why it matters to you: you’re getting exposure to infrastructure, energy, and mining capex in one ticker. Just size it like a cyclical, not a forever-compounder.

Johnson & Johnson | JNJ

Price: $181.65

The story is back to basics. JNJ is a diversified healthcare heavyweight leaning on immunology and oncology launches while managing a major loss-of-exclusivity.

Long-term growth targets look reasonable, and manufacturing investments support scale in biologics.

The pipeline of IL-23s, targeted oncology, and cell therapy gives multiple at-bats across large TAMs.

With this company you can buy on boredom. If the market yawns because LOE headlines dominate, that’s your window.

Watch uptake curves for newer indications, revenue bridges offsetting erosion, and margins as manufacturing ramps. 

For portfolio construction, JNJ can be your defensive anchor that still has upside from execution.

If you already own it, dripping dividends and reinvesting is a fine plan while you wait for new therapies to inflect.

Why it matters to you: healthcare exposure that won’t keep you up at night, with enough innovation to avoid turning into a pure bond proxy.

Clock Is Ticking (Sponsored)

Don’t Miss 2025’s Final Surge Before It’s Gone

The final quarter of 2025 will create two groups of people: those who watched their portfolios stagnate (or worse), and those who capitalized on the coming volatility.

Which group will you be in?

Our new report reveals 7 stocks positioned to thrive in the chaos, with specific entry and exit price targets for each.

This is your blueprint to potentially turn market uncertainty into your biggest advantage of the year.

The market's final big move of 2025 is coming.

By the time it's obvious, it will be too late.

Don't get left behind.

Get Your FREE Q4 Stocks Advantage Report Now!

Thermo Fisher Scientific | TMO

Price: $461.99

This is the kingpin of life sciences tools.

Near-term sentiment has been mixed as investors debate mid-cycle growth, but end-markets in pharma R&D and bioproduction are stabilizing, and share gains continue in key franchises.

Multiple is off the highs, and the long arc of more therapies, more testing, and more discovery still bends toward higher lab spend.

What you can do here is accumulate patiently. Start a position, then add on any wobbles tied to macro lab budgets or cautious guides.

Track book-to-bill in bioproduction, pharma and biotech order growth, and incremental margins as volumes recover.

If management reiterates medium-term scenarios and prints clean quarters, the market usually rewards the visibility.

Why it matters to you: if you like owning the ecosystem rather than single drug bets, this is your toolkit. It won’t moon, but it can compound.

Xcel Energy | XEL

Price: $80.05

A fire-related legal overhang is closer to resolution, with insurance covering a good chunk and guidance reaffirmed.

For a regulated utility, clearing fog matters more than headline drama.

The core thesis is straightforward with a regulated rate base growth, constructive jurisdictions, and a path through the energy transition with wind, solar, and grid upgrades.

This is another great sleep-at-night stock. If you need income plus lower beta, XEL fits, especially after periods of utilities underperforming.

Add near the low end of the recent range, and let dividend reinvestment do work. 

Keep an eye on regulatory outcomes, allowed ROEs vs. funding costs, and capex execution.

If Treasury yields drift lower into year-end, the relative bid for utilities usually improves.

Why it matters to you: When your growth names zig, this tends to zag less, and you still collect a near-3% yield.

Rocket Lab | RKLB

Price: $47.05

Two interplanetary spacecraft have arrived at Kennedy for a Mars mission built on a fast-cycle platform.

That’s not cool space trivia, it’s proof the company can design, integrate, and deliver complex buses on compressed schedules with a vertically integrated parts stack.

The setup here is a blend of recurring small-launch revenue, growing spacecraft and components sales, and optionality from bigger vehicles in development.

You should treat this stock like a barbell.

If you’re new, start with a small venture sleeve position you’re comfortable averaging into on volatility as space names can move like comets.

Your adds should line up with program milestones like propulsion loading and pre-launch tests, successful mission handoff, and new contract awards in spacecraft or national security. 

Risk management matters with this stock, though. Use a stop on the initial tranche and widen it only if execution stays clean.

You’ll want to monitor their backlog growth in space systems, cadence on medium-lift development, and margins on spacecraft vs. launch.

Why it matters to you: this is an execution story disguised as a space story. If the company keeps shipping flight-ready hardware on time, the market will pay up for schedule reliability long before the next glossy render.

Today’s mix blends a space upstart proving it can ship, an industrial geared to capex cycles, a healthcare stalwart balancing erosion with launches, a life-science toolmaker that wins with time, and a utility shedding legal risk. 

Stat of the Day: 3.3% Growth
The Atlanta Fed’s GDPNow model pegs Q3 real GDP at 3.3% annualized. Not exactly recession vibes.

In a slow-growth world, steady compounders often win the marathon, use bouts of volatility to keep adding quality.